TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
renal-cell carcinoma (advanced)
systematic review
meta-analysis
network meta-analysis
Select
angiogenesis inhibitors
mTOR inhibitor
multi target TKI
immune checkpoint inhibition
interferon
All mechanism
All type of patient
anti-PD-1
bevacizumab
combination
mTor inihibitor
TKI
VEGFR, MET AXL TKI
apitolisib
atezolizumab
cabozantinib
tivozanib
avelumab
axitinib
bevacizumab
dovitinib
everolimus
nivolumab
pazopanib
pembrolizumab
sorafenib
sunitinib
temsirolimus
1st line
2nd line
Filter
hide ongoing
show ongoing
hide ongoing
all ROB
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
all results
Show all trials
Show only trial with conclusive result
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
MA
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
Description
Synopsis
Comparison
Treatments
Patients
Characteristics
Method
Risk of bias
References
None
Tools
Indexation
Results
Global trial result
Main results
All results
All result tag
NCT results
progression or death (progression free survival PFS) (18)
death (overall survival) (13)
Options
Numeric
bar chart
forest plot
medians
Trial
Studied trt
Control trt
patients
tags
ROB
Trial result
progression or death (progression free survival PFS)
death (overall survival)
angiogenesis inhibitors
bevacizumab
CALGB 90206, 2010
bevacizumab plus interferon alfa
interferon alpha
suggesting
-29%
-14%
AVOREN, 2007
bevacizumab plus interferon alfa
interferon alpha
suggesting
-37%
-14%
Yang, 2003
bevacizumab
placebo
Exploratory
-
immune checkpoint inhibition
nivolumab
Chekmate 025 (Motzer), 2015
NCT
nivolumab
everolimus
2L
Risk of bias
suggesting
-12%
-27%
CheckMate-214, 2017
NCT
nivolumab + ipilimumab
sunitinib
1L
Risk of bias
conclusive
-18%
-32%
mTOR inhibitor
everolimus
RECORD-1, 2008
NCT
everolimus
placebo
suggesting
-70%
-17%
RECORD 3, 2014
NCT
everolimus
sunitinib
-
40%
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007
NCT
temsirolimus
interferon alpha
suggesting
-27%
INTORSECT, 2014
NCT
temsirolimus
sorafenib
negative
-13%
31%
multi target TKI
not classified
Disruptor-1
BNC105P + everolimus
everolimus
-
apitolisib
Powles, 2014
apitolisib
everolimus
-
axitinib
AXIS (Rini), 2011
NCT
axitinib
sorafenib
suggesting
-34%
Qin, 2012
axitinib
sorafenib
-
cabozantinib
METEOR, 2015
NCT
cabozantinib
everolimus
after VEGFR-targeted therapy failure
2nd line
Risk of bias
suggesting
-42%
-33%
CABOSUN, 2017
NCT
cabozantinib
sunitinib
first-line therapy in patients with intermediate- or poor-risk
1st line
Exploratory
suggesting
-34%
dovitinib
GOLD
NCT
dovitinib
sorafenib
Risk of bias
negative
-14%
pazopanib
Sternberg, 2010
pazopanib
placebo
Low risk of bias
suggesting
-54%
VEG105192, 2010
NCT
pazopanib
placebo
suggesting
-54%
-9%
COMPARZ, 2013
NCT
pazopanib
sunitinib
negative
5%
-9%
sorafenib
Escudier, 2009
sorafenib
interferon alpha
Exploratory
negative
-12%
TARGET, 2007
NCT
sorafenib
placebo
Low risk of bias
suggesting
-56%
-12%
Ratain, 2006
sorafenib
placebo
Exploratory
-
sunitinib
Motzer, 2007
NCT
sunitinib
interferon alpha
suggesting
-58%
-18%
SWITCH
NCT
sunitinib
sorafenib
-
tivozanib
TIVO-1, 2013
NCT
tivozanib
sorafenib
suggesting
-20%
25%
×
Modal title